/
Oncology
Other Solid Tumors
13
Pipeline Programs↗
10
Active Trials↗
15
Companies Involved↗
Other Solid Tumors is an emerging landscape with 13 programs across 15 companies. The most active players are Betta Pharmaceuticals Co., Ltd., Allist Pharmaceuticals, Inc., Sichuan Baili Pharmaceutical Co., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 17
Phase 26
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
77%
Small molecule
10 of 13 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 13 classified programs, each share of the total. Modality classified for 100% of 13 pipeline programs.
Analysis
Trial Status
22
clinical trials
Recruiting6 · 27%
Completed4 · 18%
Active, not recruiting4 · 18%
Unknown status4 · 18%
Terminated2 · 9%
Withdrawn1 · 5%
Other1 · 5%
Clinical Trials
Trial Activity
22 trials
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
Completed·—·Phase 1·NCT00544284·25 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)